A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: JNJ-90301900
BIOLOGICAL: Durvalumab
RADIATION: Concurrent Chemo/Radiation Therapy (cCRT)
DRUG: Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
DRUG: Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel

Sponsor

Johnson & Johnson Enterprise Innovation Inc.